United States: Healthcare: What's In The 2018 Omnibus Appropriations Law?

Last Updated: April 5 2018
Article by Kathleen P. Rubinstein and Joyce A. Cowan

The recently passed omnibus appropriations bill includes extensive funding, often at higher amounts than in fiscal year 2017, for many US healthcare agencies as well as new dollars to address the opioid crisis. Marking the eighth anniversary of the Affordable Care Act, the omnibus provides no new funding for the healthcare law.

Following months of delays and multiple short-term spending packages, the massive 2,232-page omnibus appropriations bill was signed into law by US President Donald Trump on March 23, providing $1.3 trillion in federal government funding for the remainder of the 2018 fiscal year.

Congressional leaders were able to break the funding impasse and reach bipartisan compromise by building on their agreement from February, the Bipartisan Budget Act, to raise spending caps on defense and nondefense discretionary spending.

The omnibus reflects both Democratic and Republican priorities, provides much-needed certainty to federal departments and stakeholders, and makes limited, but impactful, policy changes. Most importantly, the omnibus greatly extends and, in many cases, expands government funding to many agencies.


Missing from the omnibus is the GOP-led Affordable Care Act (ACA) stabilization package, which would have funded reinsurance programs and cost-sharing reduction subsidies. A bitter dispute over abortion policy blocked the proposal's inclusion in the spending bill. The focus now shifts to the states, where efforts to protect consumers against escalating insurance premiums have become more urgent as carriers begin filing their proposed 2019 rates soon.

Marking the eighth anniversary of the Affordable Care Act, the omnibus provides no new funding for the ACA and restricts federal funding for risk corridor payments. It also requires notification by the Centers for Medicare & Medicaid Services (CMS) to Congress before any ACA-related data or grant opportunities are released to the public as well as requires the publication of "ACA-related spending by category since its inception," including workforce information and activities involved in the administration and enforcement of the healthcare law.

Opioid Funds

The omnibus spending package includes an additional $3.6 billion, allocated across agencies, for state and local government prevention and treatment initiatives to fight the opioid epidemic, including funds to help rural communities address substance abuse disorders.

Key Highlights

In rejecting administration efforts to reduce spending for healthcare programs and agencies, the omnibus provides $88 billion for the US Department of Health and Human Services (HHS), $10 billion above the FY 2017 enacted level. It also provides for a 10% increase in funding for the Food and Drug Administration at $5.1 billion, which is $159 million more than requested.

Appropriations for CMS are equal to the FY 2017 level, and include $745 million for healthcare fraud and abuse control activities (a $20 million increase over FY 2017 but $6 million less than requested) and $182 million to reduce the backlog of more than 500,000 Medicare appeals, a $75 million increase over FY 2017.

The Health Resources & Services Administration (HRSA) also received a boost to $7 billion—9% more than FY 2017 and 21% more than requested. Funding for HRSA programs and activities includes $315 million for children's hospitals graduate medical education (CHGME) payments, an increase of $15 million, and $1.6 billion for community health centers, $135 million more than FY 2017.

Omnibus funding for the National Institutes of Health (NIH) is at an historic level in actual dollars with $37 billion in appropriations—$3 billion more than FY 2017 and 349% more than requested. The NIH budget increases funding for all NIH research programs including Alzheimer's research ($1.8 billion), mapping the human brain (BRAIN initiative) ($400 million), the All of US Research precision medicine initiative ($290 million), and the development of a universal flu vaccine ($100 million).

Although the administration previously proposed dissolving the Agency for Healthcare Research and Quality (AHRQ) and folding it into NIH, the omnibus funds AHRQ at $334 million, an increase of $10 million over the prior fiscal year.

The Centers for Disease Control (CDC) received a total of $8.3 billion in funding—14% more than FY 2017 and 38% more than requested. This includes $1.45 billion for public health preparedness and response programs aimed at responses to bioterror attacks and pandemic disease emergencies; $2.3 billion for chronic disease prevention and health promotion including HIV/AIDS, viral hepatitis, sexually transmitted diseases, and tuberculosis prevention activities; and $480 million for the establishment of a new biosafety level 4 laboratory in support of biodefense research.

The omnibus provides $5 billion for the Substance Abuse & Mental Health Services Administration (SAHMSA), a 37% increase over FY 2017 and 52% more than requested, and includes funding for programs addressing mental health ($1.5 billion) and substance abuse ($3.3 billion).

Funding levels are also maintained for most global health programs including the US President's Emergency Plan for AIDS Relief and USAID programs.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions